Stock listing
NYSE American:OSTX OS Therapies Incorporated Stock
Home listing (NYSE American) of OS Therapies Incorporated
Follow OS Therapies Incorporated into a list and get an email when it puts out news.
Share price · AMEX:OSTX
$0.803 USD -0.117 (-12.7%)
Close on Nov 20, 2026
- Day range
- $0.790 – $0.863 USDNov 20, 2026
- Volume
- 489,720 sharesNov 20, 2026
- Market cap
- $42.00M USDAt the close on Nov 20, 2026 · price × 52.30M shares outstanding
- 52-week range
- $0.580 – $2.250 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.01M USDMedian day 489,720 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:OSTX · Home | $0.803 USD | -0.117 (-12.7%) | 489,720 | $0.809 | $0.863 | $0.790 | $0.920 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:OSTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.803 | -0.117 | -12.7% | $0.809 | $0.863 | $0.790 | 489,720 | |
| $0.920 | +0.175 | +23.5% | $0.747 | $0.950 | $0.747 | 1,299,948 | |
| $0.745 | +0.064 | +9.4% | $0.680 | $0.770 | $0.647 | 1,163,406 | |
| $0.681 | -0.064 | -8.6% | $0.748 | $0.750 | $0.673 | 498,168 | |
| $0.745 | -0.005 | -0.7% | $0.710 | $0.786 | $0.680 | 806,102 | |
| $0.750 | -0.122 | -14.0% | $0.879 | $0.879 | $0.722 | 1,337,960 | |
| $0.872 | -0.018 | -2.0% | $0.896 | $0.940 | $0.860 | 327,347 | |
| $0.890 | -0.030 | -3.3% | $0.958 | $0.980 | $0.860 | 404,145 | |
| $0.920 | -0.080 | -8.0% | $0.990 | $1.080 | $0.900 | 705,893 | |
| $1.000 | +0.020 | +2.0% | $0.980 | $1.000 | $0.840 | 981,548 | |
| $0.980 | -0.170 | -14.8% | $0.986 | $1.015 | $0.580 | 3,465,731 | |
| $1.150 | -0.010 | -0.9% | $1.180 | $1.210 | $1.110 | 503,303 | |
| $1.160 | +0.010 | +0.9% | $1.160 | $1.220 | $1.150 | 439,290 | |
| $1.150 | -0.090 | -7.3% | $1.240 | $1.300 | $1.115 | 928,981 | |
| $1.240 | -0.060 | -4.6% | $1.270 | $1.280 | $1.210 | 321,618 | |
| $1.300 | +0.050 | +4.0% | $1.250 | $1.330 | $1.250 | 388,780 | |
| $1.250 | +0.020 | +1.6% | $1.240 | $1.280 | $1.220 | 273,881 | |
| $1.230 | +0.020 | +1.7% | $1.220 | $1.280 | $1.200 | 318,053 | |
| $1.210 | -0.040 | -3.2% | $1.270 | $1.270 | $1.200 | 247,655 | |
| $1.250 | 0.000 | 0.0% | $1.270 | $1.290 | $1.230 | 142,121 | |
| $1.250 | -0.020 | -1.6% | $1.270 | $1.310 | $1.240 | 344,358 | |
| $1.270 | +0.010 | +0.8% | $1.270 | $1.330 | $1.250 | 338,045 | |
| $1.260 | -0.010 | -0.8% | $1.300 | $1.340 | $1.255 | 320,657 | |
| $1.270 | -0.050 | -3.8% | $1.330 | $1.340 | $1.230 | 704,744 | |
| $1.320 | -0.090 | -6.4% | $1.420 | $1.430 | $1.300 | 529,171 | |
| $1.410 | +0.020 | +1.4% | $1.380 | $1.440 | $1.375 | 375,237 | |
| $1.390 | -0.060 | -4.1% | $1.450 | $1.480 | $1.380 | 497,347 | |
| $1.450 | -0.110 | -7.1% | $1.570 | $1.580 | $1.450 | 810,557 | |
| $1.560 | -0.060 | -3.7% | $1.610 | $1.623 | $1.560 | 247,344 | |
| $1.620 | 0.000 | 0.0% | $1.620 | $1.660 | $1.590 | 422,126 | |
| $1.620 | +0.070 | +4.5% | $1.550 | $1.680 | $1.540 | 664,816 | |
| $1.550 | +0.060 | +4.0% | $1.500 | $1.565 | $1.464 | 586,742 | |
| $1.490 | -0.110 | -6.9% | $1.710 | $1.740 | $1.470 | 6,015,385 | |
| $1.600 | -0.020 | -1.2% | $1.610 | $1.630 | $1.565 | 416,202 | |
| $1.620 | +0.010 | +0.6% | $1.625 | $1.660 | $1.620 | 233,394 | |
| $1.610 | +0.010 | +0.6% | $1.620 | $1.650 | $1.560 | 329,638 | |
| $1.600 | -0.010 | -0.6% | $1.600 | $1.670 | $1.590 | 475,091 | |
| $1.610 | -0.040 | -2.4% | $1.640 | $1.660 | $1.600 | 549,523 | |
| $1.650 | -0.010 | -0.6% | $1.660 | $1.679 | $1.610 | 353,424 | |
| $1.660 | 0.000 | 0.0% | $1.670 | $1.680 | $1.640 | 171,423 | |
| $1.660 | +0.010 | +0.6% | $1.660 | $1.670 | $1.615 | 347,757 | |
| $1.650 | -0.120 | -6.8% | $1.760 | $1.770 | $1.640 | 654,500 | |
| $1.770 | +0.030 | +1.7% | $1.760 | $1.840 | $1.740 | 600,390 | |
| $1.740 | -0.030 | -1.7% | $1.810 | $1.815 | $1.740 | 637,059 | |
| $1.770 | -0.060 | -3.3% | $1.810 | $1.830 | $1.760 | 908,579 | |
| $1.830 | +0.080 | +4.6% | $1.800 | $2.000 | $1.800 | 2,230,933 | |
| $1.750 | -0.030 | -1.7% | $1.790 | $1.820 | $1.740 | 421,327 | |
| $1.780 | +0.080 | +4.7% | $1.780 | $1.810 | $1.710 | 1,054,087 | |
| $1.700 | +0.020 | +1.2% | $1.650 | $1.790 | $1.620 | 993,722 | |
| $1.680 | -0.140 | -7.7% | $1.810 | $1.840 | $1.660 | 825,871 | |
| $1.820 | -0.040 | -2.2% | $1.870 | $1.920 | $1.810 | 547,914 | |
| $1.860 | +0.030 | +1.6% | $1.830 | $1.920 | $1.800 | 393,179 | |
| $1.830 | -0.050 | -2.7% | $1.960 | $2.015 | $1.750 | 1,767,807 | |
| $1.880 | +0.060 | +3.3% | $1.840 | $1.960 | $1.840 | 982,579 | |
| $1.820 | +0.110 | +6.4% | $1.720 | $1.840 | $1.720 | 894,277 | |
| $1.710 | +0.050 | +3.0% | $1.680 | $1.720 | $1.610 | 530,467 | |
| $1.660 | -0.030 | -1.8% | $1.680 | $1.705 | $1.630 | 400,615 | |
| $1.690 | +0.050 | +3.0% | $1.620 | $1.690 | $1.620 | 234,957 | |
| $1.640 | -0.040 | -2.4% | $1.690 | $1.690 | $1.600 | 294,984 | |
| $1.680 | +0.030 | +1.8% | $1.650 | $1.720 | $1.641 | 518,150 | |
| $1.650 | 0.000 | 0.0% | $1.650 | $1.650 | $1.600 | 351,463 | |
| $1.650 | +0.100 | +6.5% | $1.530 | $1.650 | $1.530 | 351,233 | |
| $1.550 | -0.040 | -2.5% | $1.500 | $1.550 | $1.460 | 438,883 | |
| $1.590 | +0.010 | +0.6% | $1.560 | $1.635 | $1.560 | 386,419 | |
| $1.580 | +0.120 | +8.2% | $1.500 | $1.580 | $1.450 | 369,640 |
- Ticker
- NYSE American:OSTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Oct 1, 2026
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 19 slides
Latest news
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Oct 1, 2026
Closed $1.61 (+0.6%) on Oct 1, 2026
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
Sep 24, 2026
Closed $1.66 (+0.6%) on Sep 24, 2026
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Sep 21, 2026
Closed $1.74 (-1.7%) on Sep 21, 2026
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
Sep 17, 2026
Closed $1.83 (+4.6%) on Sep 17, 2026
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Sep 15, 2026
Closed $1.78 (+4.7%) on Sep 15, 2026
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Sep 8, 2026
Closed $1.83 (-2.7%) on Sep 8, 2026
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Sep 2, 2026
Closed $1.71 (+3.0%) on Sep 2, 2026
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Aug 17, 2026
Closed $1.47 (-9.3%) on Aug 17, 2026
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Aug 13, 2026
Closed $1.60 (-0.6%) on Aug 13, 2026
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
Jul 8, 2026
Closed $1.46 (-8.2%) on Jul 8, 2026
OS Therapies Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 41 in the last 12 months · 72 in all · newest Oct 1, 2026 · oldest 2025
- Decks
- 3 decks · latest September 2026
Where OS Therapies Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:OSTX · Home listing · This page | NYSE American | United States | USD |
| BOATS:OSTX | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $41.57M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.70
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.88M | US$32.02M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.82M | US$17.89M | 48.8× | 18.6× | 3.9× | −16.1% | 0.1× | 1.51 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.70 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Olivier R. Jarry | Chief Executive Officer |
| Paul Romness | Chair, Chief Executive Officer, President |
| Chris Acevedo | Chief Financial Officer |
| Gerald Commisiong | Chief Business Officer |
| Jack Doll | Chief of Staff |
| John Ciccio | Chief Operations Officer, Syneos Health |
| Kerry Clem | Chief Commercial Officer |
| Robert Petit | Chief Medical & Scientific Officer, Founding Scientist (OST-HER2) |
Board
| Director | Role |
|---|---|
| Paul Romness | Chair, Chief Executive Officer, President |
| Craig Eagle | Director |
| John Ciccio | Chief Operations Officer, Syneos Health |
| Karim Galzahr | Director |
| Theodore Search | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +9.4% |
| Q2 2026 | Aug 14, 2026 · After close | −9.3% |
| Q1 2026 | May 18, 2026 · Before open | −8.0% |
| Q3 2025 | Nov 14, 2025 · After close | −5.0% |
| Q2 2025 | Aug 18, 2025 · After close | −1.4% |
| Q1 2025 | May 15, 2025 · After close | −1.2% |
| Q4 2024 | Mar 31, 2025 | −17.9% |
| Q3 2024 | Nov 15, 2024 · Before open | 0.0% |
| Q2 2024 | Aug 28, 2024 | −10.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 19 slides | September 2026 |
| Biomarker-focused Conference Call (April 2026) | Conference | 35 slides | Apr 30, 2026 |
| Investor Presentation (October 2025) | Investor deck | 28 slides | Oct 17, 2025 |
Financings
| Raise | Date |
|---|---|
| Debt financing Tranche closed: US$5M raised | Aug 17, 2026 |
| Warrant exercise of common stock purchase warrants exercised or pre-funded for cash under warrant inducement Announced: US$7.53M · Ceros Capital Markets, a division of Ceros Financial Services, Inc. Dealers: Ceros Capital Markets, a division of Ceros Financial Services, Inc. (lead) Use of proceeds: OST-HER2 regulatory filings and commercial preparation, OS Animal Health spinoff preparations, and general corporate purposes | Jan 12, 2026 |
| Warrant exercise of outstanding warrants with $1.12 exercise price exercised under warrant inducement and exchange offer Closed: US$3.7M raised · US$1.12 a share · Warrants at US$3 · Ceros Financial Services, Inc. Dealers: Ceros Financial Services, Inc. (lead) Use of proceeds: Primarily to accelerate OST-HER2 commercial launch preparations in osteosarcoma in the United States | Sep 2, 2025 |
| Shares under Equity Purchase Agreement (equity line of credit) Cancelled: raise Buyers: Square Gate Capital Master Fund, LLC — Series 3 | Aug 26, 2025 |
| At-the-market programme of common stock Announced: up to US$18M · B. Riley Securities +1 Dealers: B. Riley Securities, JonesTrading | Aug 19, 2025 |
| Warrant exercise of warrants exercised under warrant exercise inducement and exchange offer Closed: US$1.76M raised · US$1.12 a share · Warrants at US$3 for 60 months Use of proceeds: Regulatory and pre-commercial work for OST-HER2 approvals, OS Animal Health alternatives, OST-504 study close-out, AI tADC modeling, general corporate | Jul 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Jul 31, 2024.
- Price
- US$4.00 a share
- Shares offered
- 1,600,000 shares of common stock
- Offering size
- US$6.4 million
- Underwriters' option
- Up to 240,000 more shares
- Listing
- OSTX on NYSE American
- Underwriter
- Brookline Capital Markets
- Shares delivered
- On or about Aug 2, 2024
Steps
| Step | When |
|---|---|
| Filed publicly | May 30, 2024 |
| Amended twice | Newest Jun 13, 2024 |
| Shares registered with an exchange | Jul 30, 2024 |
| Declared effective by the SEC | Jul 31, 2024 |
| Final prospectus, with the price | Aug 1, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 1, 2024 |
| EFFECT · Notice that a registration is effective | Jul 31, 2024 |
| CERT · Exchange's certificate of listing | Jul 30, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 30, 2024 |
| CORRESP · Letter to the SEC | Jul 26, 2024 |
| CORRESP · Letter to the SEC | Jul 26, 2024 |
| CORRESP · Letter to the SEC | Jun 26, 2024 |
| CORRESP · Letter to the SEC | Jun 26, 2024 |
| CORRESP · Letter to the SEC | Jun 25, 2024 |
| CORRESP · Letter to the SEC | Jun 25, 2024 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 20, 2024 |
| CORRESP · Letter to the SEC | Jun 20, 2024 |
| CORRESP · Letter to the SEC | Jun 18, 2024 |
| CORRESP · Letter to the SEC | Jun 18, 2024 |
| CORRESP · Letter to the SEC | Jun 13, 2024 |
| S-1/A · Registration statement, amended | Jun 13, 2024 |
| UPLOAD · Letter from the SEC | Jun 11, 2024 |
| CORRESP · Letter to the SEC | Jun 7, 2024 |
| S-1/A · Registration statement, amended | Jun 7, 2024 |
| S-1 · Registration statement | May 30, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 1, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 363.1K | 2.78K | 4.22K | 805 | 1.16M | 4.25K |
| Gross profit | -363.1K | -2.78K | -4.22K | -805 | -1.16M | -4.25K |
| Research and development | 16.4M | 2.84M | 3.22M | 3.29M | 2.17M | 602 |
| Selling, general and administrative | 12.3M | 3.97M | 1.12M | 1.15M | 1.50M | 795 |
| Operating income | -28.7M | -6.81M | -4.34M | -4.45M | -4.84M | -5.65K |
| Depreciation and amortization | 363.1K | 2.78K | 4.22K | 805 | 805 | 67.0K |
| EBITDA | -28.3M | -6.81M | -4.34M | -4.45M | -4.84M | 61.4K |
| Interest expense | 0 | 2.05M | 3.45M | 1.81M | 2.58M | 461.8M |
| Income before tax | -28.8M | -8.88M | -7.79M | -6.25M | -7.42M | -6.03K |
| Net income | -28.8M | -8.88M | -7.79M | -6.25M | -7.42M | -6.03K |
| Earnings per share, basic | -0.98 | -1.28 | -1.46 | -0.27 | -0.32 | -0.00 |
| Earnings per share, diluted | -0.98 | -1.28 | -1.46 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 269.8K | 5.53M | 39.0K | 171.5K | 80.8K | 1.23B |
| Short-term investments | 5.53B | |||||
| Receivables | 1.15K | 231.1K | 430.5M | |||
| Current assets | 332.9K | 5.53M | 790.0K | 496.8K | 312.8K | 1.68B |
| Property, plant and equipment | 2.49K | 5.27K | 8.05K | |||
| Total assets | 6.84M | 5.54M | 798.1K | 509.1K | 325.9K | 1.68B |
| Accounts payable | 9.94M | 1.66M | 2.72M | 1.23M | 856.5K | 40.0K |
| Current liabilities | 11.8M | 4.63M | 24.7M | 6.15M | 3.50M | 2.10B |
| Long-term debt | 10.3M | 7.07M | ||||
| Total debt | 6.05M | 14.6M | 10.3M | 7.07M | 6.77B | |
| Total liabilities | 11.9M | 4.73M | 24.8M | 18.1M | 11.8M | 8.00B |
| Shareholders' equity | -6.10M | -3.27M | -24.0M | -17.6M | -11.5M | -6.33B |
| Shares outstanding | 37.1M | 20.9M | 5.34M | 23.1M | 23.1M | 8.42M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -14.2M | -7.28M | -3.01M | -3.79M | -4.40M | -2.41B |
| Capital spending | -466.4K | 0 | 0 | 0 | -11.9K | -2.01M |
| Free cash flow | -14.7M | -7.28M | -3.01M | -3.79M | -4.41M | -2.42B |
| Cash from investing | -466.4K | 1.15K | 230.9K | 200.5K | 158.3M | |
| Cash from financing | 9.44M | 12.8M | 2.87M | 3.65M | 3.05M | 3.48B |
| Dividends paid | -31.3M | |||||
| Share buybacks | 6.40B | |||||
| Change in cash | -5.26M | 5.50M | -132.5K | 90.7K | -1.15M | 1.23B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| D | Oct 23, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 5, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Sep 18, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2026 | Current report | SEC |
| 424B7 · Prospectus | Sep 10, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 9, 2026 | Management or board change | SEC |
| D | Aug 25, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 21, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 21, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Material contract | SEC |
| 8-K · Current report | Aug 6, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 29, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Jul 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 24, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Jul 23, 2026 | Insider trade | SEC |
| D | Jul 15, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Jul 7, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 18, 2026 | Quarterly report | SEC |
| 5/A · Annual statement of ownership, amended | May 15, 2026 | Insider trade | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| 8-K · Current report | Apr 2, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 2, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 424B7 · Prospectus | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| D | Mar 6, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2026 | Current report | SEC |
| D | Jan 20, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Material contract | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Oct 31, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 21, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| 424B7 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| D | Sep 10, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 26, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Aug 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 25, 2025 | Meeting notice | SEC |
| 424B5 · Prospectus | Aug 25, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 21, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 19, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 18, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | Aug 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Aug 15, 2025 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 4, 2025 | Offer document | SEC |
| D | Jul 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 27, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jun 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 28, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 23, 2025 | Offer document | SEC |
| 8-K · Current report | May 16, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 24, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 24, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 21, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Apr 21, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Mar 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 28, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Feb 28, 2025 | Meeting notice | SEC |
| 3/A · Initial statement of ownership, amended | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 14, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 7, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 6, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Feb 5, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 31, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2025 | Material contract | SEC |
| D | Jan 21, 2025 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jan 14, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 13, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 3, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 3, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 30, 2024 | Material contract | SEC |
| S-1/A · Registration statement, amended | Nov 27, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 27, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 20, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 15, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2024 | Explanation request | SEC |
| S-1 · Registration statement | Nov 12, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 1, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Oct 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Aug 28, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 22, 2024 | Current report | SEC |
| 8-K · Current report | Aug 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Aug 1, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 1, 2024 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Jul 30, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jul 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 26, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 25, 2024 | Other filings | SEC |
This page holds 200 of 248 filings. Open Filings
Cap table
Built by 6ix from OS Therapies Incorporated’s releases · as of Nov 13, 2026
- Common shares
- 52,300,709
- Fully diluted
- 52,300,709
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 52,300,709 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.00 · expiry not stated |
| Warrants · US$3.00 · expire about Jul 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 52,300,709 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Knuettel Francis II Other companies: Splash Beverage Group, Inc. (nv) (Director · Since at least Apr 27, 2026); Beeline Holdings, Inc. (Director · Since at least May 14, 2025); Pelthos Therapeutics Inc. (CFO, Treas & Secty · Since at least Feb 15, 2024); Tevogen Bio Holdings Inc. (Chief Financial Officer · Jun 7, 2023 – Jun 7, 2023 · Past); Oceantech Acquisitions I Corp (Chief Financial Officer · Mar 13, 2023 – Mar 13, 2023 · Past); CDT Equity Inc. (Director · Feb 2, 2022 – Feb 2, 2022 · Past); Forum Markets, Incorporated (Director · Jul 2, 2021 – Sep 4, 2023 · Past); Unrivaled Brands Inc (CEO and President, Director · Jun 7, 2021 – Jun 18, 2021 · Past); SCWorx Corp. (Director · Feb 1, 2019 – Nov 26, 2019 · Past); Aqua Metals, Inc. (Chief Financial Officer · May 9, 2018 – Jun 15, 2018 · Past); Spindle Inc (Director · Oct 21, 2015 – Jun 30, 2017 · Past); MARA Holdings, Inc. (CHIEF FINANCIAL OFFICER · May 15, 2014 – Nov 3, 2014 · Past) | Chief Financial Officer · Since at least Nov 10, 2026 |
| Colin Goddard Other companies: Endocyte Inc (Director · Nov 7, 2013 – Dec 21, 2018 · Past); Human Genome Sciences Inc (Director · Dec 13, 2010 – Jul 30, 2012 · Past); Osi Pharmaceuticals Inc (Chief Executive Officer, Director · Jun 2, 2006 – Jun 7, 2010 · Past) | Director · Jul 31, 2024 – Dec 31, 2024 · Past |
| Craig Eagle Other companies: Guardant Health, Inc. (Chief Medical Officer · Since at least May 4, 2021); Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Q/C Technologies, Inc. (Director · Apr 16, 2021 – Jun 7, 2023 · Past) | Director · Since at least Jul 1, 2026 |
| Olivier R. Jarry Other companies: DarioHealth Corp. (See Remarks · Aug 30, 2018 – Jan 28, 2020 · Past); Precigen, Inc. (SVP--Consumer Sector · Jun 11, 2015 – Jun 11, 2015 · Past) | Chief Executive Officer · Since at least Oct 28, 2024 |
| Kerry Clem Other companies: Acorda Therapeutics Inc (Chief Commercial Officer · Sep 9, 2021 – Mar 31, 2023 · Past) | Chief Commercial Officer · Since at least Oct 1, 2026 |
| Robert Petit Other companies: Advaxis Inc (Chief Scientific Officer · May 3, 2013 – Nov 5, 2018 · Past) | Chief Medical & Scientific Officer, Founding Scientist (OST-HER2) · Since at least Jul 31, 2024 |
| Avril Suzette McKean-Dieser | Director · Since at least Oct 28, 2024 |
| Chris Acevedo | Chief Financial Officer · Since at least Jul 2, 2026 |
| Christopher P Acevedo | Chief Financial Officer · Since at least Jul 31, 2024 |
| Gerald Commisiong | Chief Business Officer · Since at least Nov 4, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Jack Doll | Chief of Staff · Since at least Jul 10, 2025 |
| Joacim Borg | Director · Jul 31, 2024 – Jul 31, 2024 · Past |
| John Ciccio | Chief Operations Officer, Syneos Health · Since at least Jul 31, 2024 |
| Karim Galzahr | Director · Since at least Jan 28, 2025 |
| Paul Romness | Chair, Chief Executive Officer, President · Since at least Jul 31, 2024 |
| Theodore Search | Director · Since at least Jul 31, 2024 |
Log in to ask 6ix AI your own questions about OS Therapies Incorporated.